Mod­er­na 'laser-fo­cused' on AI, from clin­i­cal de­vel­op­ment to mar­ket­ing: #Can­nes­Lions2023

When it comes to ar­ti­fi­cial in­tel­li­gence, Mod­er­na is all in.

Chief brand of­fi­cer Kate Cronin took the stage Tues­day at this year’s Cannes Li­ons In­ter­na­tion­al Fes­ti­val of Cre­ativ­i­ty to dis­cuss how the com­pa­ny is us­ing AI and oth­er dig­i­tal tools to dri­ve in­clu­siv­i­ty.

“We’re em­bed­ding AI in every­thing that we do,” she said in an in­ter­view with End­points News. 

That in­cludes re­cruit­ing for and con­duct­ing clin­i­cal tri­als, she said, ref­er­enc­ing the com­pa­ny’s land­mark COVE study eval­u­at­ing its first-gen­er­a­tion mR­NA-based Covid-19 vac­cine. Af­ter emerg­ing as an ear­ly leader in the race for a Covid vac­cine, Mod­er­na took a step back in 2020, slow­ing Phase III en­roll­ment to re­cruit a more di­verse tri­al pop­u­la­tion. Re­searchers used AI to learn the like­ly de­mo­graph­ics of cer­tain zip codes and pre­dict at­tri­tion to bet­ter dri­ve re­cruit­ment and re­ten­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER